JANX Stock Analysis: Janux Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.011m USD | 12M Return: -21% | US47103J1051 | Charts, Fundamentals & Technical Analysis

Cancer Immunotherapy, Prostate Cancer, Solid Tumors, Autoimmune Diseases
Total Rating 28
Safety 60
Buy Signal 0.09
Biotechnology
Industry Rotation: -20.0
Market Cap: 1.01B
Avg Turnover: 14.2M
Risk 3d forecast
Volatility83.4%
VaR 5th Pctl12.4%
VaR vs Median-7.93%
Reward TTM
Sharpe Ratio0.10
Rel. Str. IBD64.3
Rel. Str. Peer Group55.3
Character TTM
Beta0.875
Beta Downside1.001
Hurst Exponent0.411
Drawdowns 3y
Max DD81.78%
CAGR/Max DD0.29
CAGR/Mean DD0.50
EPS (Earnings per Share) EPS (Earnings per Share) of JANX over the last years for every Quarter: "2021-09": -0.26, "2021-12": -0.33, "2022-03": -0.32, "2022-06": -0.41, "2022-09": -0.4, "2022-12": -0.39, "2023-03": -0.42, "2023-06": -0.42, "2023-09": -0.25, "2023-12": -0.25, "2024-03": -0.3, "2024-06": -0.11, "2024-09": -0.51, "2024-12": -0.36, "2025-03": -0.38, "2025-06": -0.55, "2025-09": -0.39, "2025-12": -0.51, "2026-03": -0.39, "2026-06": -0.35,
Last SUE: -0.70
Qual. Beats: 0
Revenue Revenue of JANX over the last years for every Quarter: 2021-09: 1.159, 2021-12: 1.616, 2022-03: 1.589, 2022-06: 2.365, 2022-09: 1.813, 2022-12: 2.845, 2023-03: 2.048, 2023-06: 1.057, 2023-09: 2.517, 2023-12: 2.461, 2024-03: 1.252, 2024-06: 8.897, 2024-09: 0.439, 2024-12: -8.512, 2025-03: 0, 2025-06: 0, 2025-09: 10, 2025-12: 7.88, 2026-03: 3.733, 2026-06: 10.267,
Rev. CAGR: 11.23%
Rev. Trend: 74.8%
Last SUE: -1.98
Qual. Beats: -1

Warnings

High Debt While Negative Cash Flow

Tailwinds

Avwap Ph Week

Seasonality 5.3 years of data

Jan -2.8% 0
Feb -10.9% 22
Mar -16.8% 27
Apr +24.4% 47
May -12.6% 42
Jun +2.1% 26
Jul +4.5% 11
Aug -1.1% 9
Sep +5.9% 0
Oct +17.3% 28
Nov +1.1% 0
Dec +9.2% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: JANX Janux Therapeutics

Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapy drug candidates for cancer and autoimmune diseases using three proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its lead candidates include JANX007, in Phase 1 trials for metastatic castration-resistant prostate cancer, JANX008, in Phase 1 trials targeting multiple solid tumor types, and JANX011, a CD19-targeted candidate aimed at autoimmune diseases. The company also has strategic research and development collaborations with Merck Sharp & Dohme and Bristol Myers Squibb to advance its pipeline.

Founded in 2017 and headquartered in San Diego, California, Janux is a small-cap U.S. biotechnology firm listed on NASDAQ under the ticker JANX. As a clinical-stage company without approved commercial products, its business model relies on advancing candidates through early-stage trials and partnering with larger pharmaceutical companies to fund late-stage development, a common structure in the oncology biotech sector where capital-intensive research is offset by licensing deals and milestone payments from established drugmakers.

Headlines to Watch Out For
  • JANX007 PSMA prostate cancer Phase 1 data catalyst
  • Merck and Bristol Myers Squibb partnership milestones advance pipeline
  • Cash runway extends through key clinical readouts
Piotroski VR-10 (Strict) 1.0
Net Income: -102.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.04 > 0.02 and ΔFCF/TA 1.72 > 1.0
NWC/Revenue: 2.90k% < 20% (prev 9.30k%; Δ -6.40k% < -1%)
CFO/TA -0.04 > 3% & CFO -41.3m > Net Income -102.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 16.35 > 1.5 & < 3
Outstanding Shares: last quarter (62.9m) vs 12m ago 1.67% < -2%
Gross Margin: 93.64% > 18% (prev -631.1%; Δ 724.7% > 0.5%)
Asset Turnover: 3.13% > 50% (prev 1.03%; Δ 2.10% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.92 (Total Current Assets 983.3m - Total Current Liabilities 60.2m) / Total Assets 1.01b
B: -0.39 (Retained Earnings -397.7m / Total Assets 1.01b)
C: -0.11 (EBIT TTM -112.3m / Avg Total Assets 1.02b)
D: 11.65 (Book Value of Equity 928.0m / Total Liabilities 79.7m)
Altman-Z'' = 16.21 = AAA
Beneish M -2.06
DSRI: 0.37 (Receivables 6.33m/5.69m, Revenue 31.9m/10.6m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.09 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: 3.01 (Revenue 31.9m / 10.6m)
TATA: -0.06 (NI -102.6m - CFO -41.3m) / TA 1.01b)
Beneish M = -2.06 (Cap -4..+1) = BB
What is the price of JANX shares?

As of October 08, 2026, the stock is trading at USD 17.92 with a total of 1,210,063 shares traded. Over the past week, the price has changed by +3.70%, over one month by -10.58%, over three months by +10.96% and over the past year by -21.02%.

Current recommended Stop Loss: 16.50 (which is 7.9% or 1.9 ATR below the current price).

Is JANX a buy, sell or hold?

Janux Therapeutics has received a consensus analysts rating of 4.61. Therefore, it is recommended to buy JANX.

  • StrongBuy: 14
  • Buy: 2
  • Hold: 1
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the JANX price?
Analysts Target Price 36.2 102.2%
Janux Therapeutics (JANX) - Fundamental Data Overview as of 07 October 2026
Market Cap USD = 1.01b (1.01b USD * 1.0 USD.USD)
P/S = 42.1334
P/B = 1.0884
Revenue TTM = 31.9m USD
EBIT TTM = -112.3m USD
EBITDA TTM = -110.4m USD
Long Term Debt = 18.4m USD (estimated: total debt 21.0m - short term 2.55m)
Short Term Debt = 2.55m USD (from shortTermDebt, last quarter)
Debt = 21.0m USD (from shortLongTermDebtTotal, last quarter) (leases 21.0m already included)
Net Debt = -949.9m USD (calculated: Debt 21.0m - CCE 970.9m)
Enterprise Value = 61.3m USD (1.01b + Debt 21.0m - CCE 970.9m)
 Interest Coverage Ratio = unknown (Ebit TTM -112.3m / Interest Expense TTM 0.0)
 EV/FCF = -1.46x (Enterprise Value 61.3m / FCF TTM -41.9m)
FCF Yield = -68.42% (FCF TTM -41.9m / Enterprise Value 61.3m)
 FCF Margin = -131.5% (FCF TTM -41.9m / Revenue TTM 31.9m)
 Net Margin = -321.8% (Net Income TTM -102.6m / Revenue TTM 31.9m)
 Gross Margin = 93.64% ((Revenue TTM 31.9m - Cost of Revenue TTM 2.03m) / Revenue TTM)
Gross Margin QoQ = none% (prev 87.44%)
Tobins Q-Ratio = 0.06 (Enterprise Value 61.3m / Total Assets 1.01b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 21.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -88.7m (EBIT -112.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.35 (Total Current Assets 983.3m / Total Current Liabilities 60.2m)
Debt / Equity = 0.02 (Debt 21.0m / totalStockholderEquity, last quarter 928.0m)
 Debt / EBITDA = 8.60 (negative EBITDA) (Net Debt -949.9m / EBITDA -110.4m)
 Debt / FCF = 22.66 (negative FCF - burning cash) (Net Debt -949.9m / FCF TTM -41.9m)
 Total Stockholder Equity = 950.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.06% (Net Income -102.6m / Total Assets 1.01b)
RoE = -10.79% (Net Income TTM -102.6m / Total Stockholder Equity 950.7m)
RoCE = -11.59% (EBIT -112.3m / Capital Employed (Equity 950.7m + L.T.Debt 18.4m))
 RoIC = -9.35% (negative operating profit) (NOPAT -88.7m / Invested Capital 948.5m)
 WACC = 8.88% (E(1.01b)/V(1.03b) * Re(9.06%) + D(21.0m)/V(1.03b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.01 | Cagr: 11.72%
 [DCF] Fair Price = unknown (Cash Flow -41.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.70 | # QB: 0
Revenue Correlation: 74.80 | Revenue CAGR: 11.23% | SUE: -1.98 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-0.49 | Chg30d=+2.28% | Revisions=-21% | Analysts=14
EPS current Year (2026-12-31): EPS=-1.73 | Chg30d=+0.00% | Revisions=+13% | GrowthEPS=+5.4% | GrowthRev=+194.2%
EPS next Year (2027-12-31): EPS=-2.62 | Chg30d=+0.00% | Revisions=-13% | GrowthEPS=-51.5% | GrowthRev=-72.5%
[Analyst] Revisions Ratio: -8% (up=16, down=19)